Hemostemix Inc. (CVE:HEM – Get Free Report) reached a new 52-week low during trading on Tuesday . The stock traded as low as C$0.05 and last traded at C$0.06, with a volume of 40000 shares changing hands. The stock had previously closed at C$0.06.
Hemostemix Stock Down 8.3 %
The company’s fifty day moving average is C$0.07 and its 200 day moving average is C$0.08. The stock has a market cap of C$4.94 million, a PE ratio of -1.38 and a beta of 0.55.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia in Canada and the United States.
Read More
- Five stocks we like better than Hemostemix
- What Are Dividend Challengers?
- Bear Market Funds to Watch This Year
- How to Calculate Options Profits
- 3 Steel Stocks Could Soar on New China Tariffs
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- What’s Driving Tesla Lower Ahead of its Earnings?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
